[Plasma suPAR level in patients with multiple myeloma].

Area of Science:

• Biochemistry
• Hematology
• Oncology

Context:

• Multiple myeloma is a hematological malignancy characterized by uncontrolled proliferation of plasma cells.
• Diagnostic and prognostic biomarkers are crucial for managing multiple myeloma.
• Soluble urokinase plasminogen activator receptor (suPAR) is implicated in various inflammatory and malignant processes.

Purpose:

• To investigate the diagnostic and prognostic value of plasma suPAR levels in multiple myeloma.
• To compare suPAR levels across different multiple myeloma subtypes.
• To explore the correlation between suPAR levels and established clinical parameters.

Summary:

• Plasma suPAR levels were significantly higher in 26 multiple myeloma patients (4.31±1.67 ng/ml) compared to controls (1.87±0.27 ng/ml) (p<0.01).
• While IgM subtype showed the highest suPAR levels (6.18±3.61 ng/ml), all subtypes exhibited elevated levels compared to controls.
• suPAR levels correlated with blood sedimentation rate, creatinine, hemoglobin, plasma cell ratio, and M protein.

Impact:

• Plasma suPAR may serve as a valuable biomarker for predicting the development and prognosis of multiple myeloma.
• This finding could lead to improved patient stratification and personalized treatment strategies.
• Further research into suPAR's role could uncover novel therapeutic targets in multiple myeloma.